NeurAxis Expands Health Coverage, Enhancing Access for Families
NeurAxis Expands Health Insurance Coverage for Families
NeurAxis, Inc. is making significant strides to improve access to its innovative medical technology by announcing new health insurance policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS). This decision affects two major health insurers, providing coverage for approximately 700,000 members. The expansion is a critical development, contributing to a growing total coverage that now reaches 53 million lives across the nation, with additional coverage decisions from other major insurers anticipated soon.
About the Revolutionary IB-Stim Technology
The technology behind NeurAxis's PENFS treatment, known as IB-Stim, boasts FDA clearance specifically for addressing functional abdominal pain linked to irritable bowel syndrome (IBS) and Pediatric Functional Dyspepsia, impacting adolescents aged 8 to 21. This non-invasive device works by delivering mild electrical impulses targeted at the cranial nerve bundles in the ear, offering a novel solution in a landscape where traditional drug therapies for similar conditions are lacking—especially for children. These medications often come with a lack of proven efficacy, alongside the potential for significant side effects, making IB-Stim an important alternative.
CEO Brian Carrico's Vision
Brian Carrico, the CEO of NeurAxis, expressed enthusiasm about the new insurance coverage, highlighting its importance in making their therapy more accessible and affordable for patients suffering from abdominal pain associated with IBS and Pediatric Functional Dyspepsia. Carrico noted that these recent developments mark an essential turning point for the company, particularly as IB-Stim is now recognized in the treatment guidelines of leading pediatric academic societies for Functional Abdominal Pain in IBS. This endorsement is expected to encourage more comprehensive policy coverage and reimbursement processes, which will ultimately broaden the availability of this treatment for families in need.
Upcoming Developments
Looking ahead, NeurAxis is set to activate a Category I CPT code for PENFS, effective from January 1, 2026. This designation will enhance the valuation of the PENFS procedure, improving reimbursement capabilities and encouraging wider adoption of IB-Stim across pediatric and children's hospitals. With a strong financial position, the company is ready to meet the growing demand for their services, which are urgently needed as families face chronic health challenges.
About NeurAxis, Inc.
NeurAxis, Inc. is committed to developing cutting-edge neuromodulation therapies aimed at treating chronic conditions affecting both children and adults. With their proprietary technology, IB-Stim™—which utilizes the principles of Percutaneous Electrical Nerve Field Stimulation—the company is at the forefront of providing relief and hope to patients struggling with debilitating symptoms. Ongoing clinical trials continue to explore the capabilities of PENFS in addressing various pediatric and adult health conditions, demonstrating NeurAxis's dedication to expanding treatment options in the healthcare landscape.
Frequently Asked Questions
What is NeurAxis and what do they specialize in?
NeurAxis, Inc. is a medical technology firm focused on neuromodulation therapies designed to treat chronic conditions in both children and adults, including functional abdominal pain.
What is IB-Stim?
IB-Stim is NeurAxis's FDA-cleared device that provides a non-invasive treatment for functional abdominal pain associated with irritable bowel syndrome (IBS) and Pediatric Functional Dyspepsia.
How many lives does NeurAxis's health coverage affect?
With the latest announcement, NeurAxis's health insurance coverage for PENFS now positively impacts around 53 million lives nationwide.
What recent developments have occurred with NeurAxis?
NeurAxis has expanded its insurance coverage and received a pivotal endorsement from leading pediatric academic societies, enhancing treatment accessibility.
When is the CPT code for PENFS expected to activate?
The Category I CPT code for PENFS is set to activate on January 1, 2026, which will assist in improving reimbursement and adoption rates for the procedure.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.